医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NASHVILLE, Tenn.

A international trio of distinguished researchers presenting clinical trial outcomes today at the American Association of Clinical Endocrinologists’ (AACE) 24^th Annual Scientific and Clinical Congress shared favorable results for:

• The world’s first commercially available non-statin drug to reduce elevated triglycerides in type 2 diabetes patients
• An insulin-independent, blood glucose-lowering drug’s effects on pancreatic beta cells, and
• Laser ablation for thyroid nodules

Indian Academy of Diabetes President Dr. Shashank Joshi highlighted a nine-month study conducted in India that examined the safety and efficacy of saroglitazar, a novel drug that offers both lipid and glucose-lowering effects targeted at treating type 2 diabetes patients whose diabetic dyslipidemia or hypertriglyceridemia were not controlled by statins alone. Diabetic dyslipidemia is a condition featuring elevated levels of total cholesterol, LDL (bad) cholesterol and triglycerides and a decrease in HDL (good) cholesterol; hypertriglyceridemia denotes higher-than-normal levels of fat in a person’s blood.

The study showed significant improvements in triglycerides, total cholesterol, high-density cholesterol and HbA1c levels in 787 patients with diabetic dyslipidemia who were prescribed saroglitazar once daily, without an accompanying increase in body weight or serious adverse events.

An examination of the effects of glycemic control medication Dapagliflozin on beta-cell function and insulin resistance in adults with type 2 diabetes showed substantial improvement in both functions, providing strong clinical support that hyperglycemia, per se, contributes to both of these core defects in type 2 diabetes. The findings were presented by Dr. Carolina Solis-Herrera of the University of Texas Health Science Center at San Antonio

A once-a-day oral treatment taken as an adjunct to diet and exercise, Dapagliflozin helps lower blood glucose levels by filtering excess glucose out of the blood and preventing its reabsorption in to the body by the kidneys. The excess glucose is then eliminated through urine.

Dr. Enrico Papini, Director, Department of Endocrinology and Metabolism, Ospedale Regina Apostolorum, Albano, Rome, revealed the results of a retrospective, multicenter study of 1,531 patients who underwent 1,837 image-guided laser ablation therapy (LAT) treatments in Italy for benign thyroid nodules, which demonstrated both favorable clinical results and a well-tolerated procedure.

For more information about the AACE 24^th Annual Scientific and Clinical Congress, please visit media.aace.com or follow us on our official Twitter account at #AACE15.

About the American Association of Clinical Endocrinologists (AACE)

The American Association of Clinical Endocrinologists (AACE) represents more than 7,000 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. The majority of AACE members are certified in Diabetes, Endocrinology and Metabolism and concentrate on the treatment of patients with endocrine and metabolic disorders including diabetes, thyroid disorders, osteoporosis, growth hormone deficiency, cholesterol disorders, hypertension and obesity. Visit our website at www.aace.com.

About the American College of Endocrinology (ACE)

The American College of Endocrinology (ACE) is the educational and scientific arm of the American Association of Clinical Endocrinologists (AACE). ACE is the leader in advancing the care and prevention of endocrine and metabolic disorders by: providing professional education and reliable public health information; recognizing excellence in education, research and service; promoting clinical research and defining the future of Clinical Endocrinology. For more information, please visit www.aace.com/college.